What is Amaryl?
Amaryl was the original brand of glimepiride, a sulfonylurea that lowers blood sugar by stimulating insulin release in adults with type 2 diabetes. The Amaryl brand, approved in 1995, is listed as discontinued, and generic glimepiride tablets are now supplied instead. Its main risk is low blood sugar. In a paediatric trial it did not match metformin, and it is advised against in children.1
Approved products and generic therapeutic-equivalence ratings are listed in the FDA Orange Book.3
In a 24-week paediatric trial, 272 children aged 8 to 17 with type 2 diabetes were randomised to glimepiride or metformin; the difference in HbA1c favoured metformin, and the trial did not meet its goal of showing a similar reduction.1
Both children new to treatment and those switching from other diabetes tablets took part, and the latter stopped their previous medicine before randomisation without a washout period.
Glimepiride is advised against in children because of adverse effects on body weight and low blood sugar seen in paediatric studies.
In a three-month titration study in people with kidney impairment, with creatinine clearance of 10 to 60 mL/min, the findings supported starting all such patients at the lowest dose.
Like other sulfonylureas, glimepiride carries a labelled warning about a possible increase in cardiovascular mortality.
Amaryl is one of the diabetes medicines; Duetact pairs glimepiride with pioglitazone.
